Full Length Research Paper
References
|
Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA (2009). Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 53(9):3628-3634. Crossref |
||||
|
Al-Sweih NA, Al-Hubail MA, Rotimi VO (2011). Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals. J. Chemother. 23(1):13-16. Crossref |
||||
|
Arroyo LA, Mateos I, González V, Aznar J (2009). In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob. Agents Chemother. 53(3):1295-1296. Crossref |
||||
|
Bergogne-Berezin E, Towner KJ (1996). Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9(2):148-165. Pubmed |
||||
|
Chang KC, Lin MF, Lin NT, Wu WJ, Kuo HY, Lin TY, Yang TL, Chen YC, Liou ML (2012). Clonal spread of multidrug-resistant Acinetobacter baumannii in eastern Taiwan. J. Microbiol. Immunol. Infect. 45(1):37-42. Crossref |
||||
|
Davis KA, Moran KA, Mcallister CK, Gray PJ (2005). Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg. Infect. Dis. 11(8):1218-1224. Crossref |
||||
| Elmanama AA (2006). Antimicrobial resistance of Acinetobacter spp. isolated from pus specimens from AL-Shifa Hospital, Gaza, Palestine. J. Al-Aqsa Unv. 10(S.E.):59-68. | ||||
|
Fiori A, Van Dijck P (2012). Potent synergistic effect of doxycycline with fluconazole against Candida albicans is mediated by interference with iron homeostasis. Antimicrob. Agents Chemother. 56(7):3785-3796. Crossref |
||||
|
Giamarellou H, Antoniadou A, Kanellakopoulou K (2008). Acinetobacter baumannii: a universal threat to public health? Int. J. Antimicrob. Agents. 32(2):106-119. Crossref |
||||
|
Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC (2003). Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 47(3):905-909. Crossref |
||||
| Isenberg HD (2004). Synergism Testing: Broth Microdilution Checkerboard and broth Macrodilution Methods. In: Isenberg, H. D. ed. Clinical Microbiology Procedures Handbook. Washington, USA: ASM Press. | ||||
| Karaiskos I, Galani L, Baziaka F, Giamarellou H (2013). Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int. J. Antimicrob. Agents 41(6):499-508. | ||||
|
Kuo SC, Chang SC, Wang HY, Lai JF, Chen PC, Shiau YR, Huang IW, Lauderdale TL (2012). Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program. BMC Infect. Dis. 12:200. Crossref |
||||
|
Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C (2007). Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin. Infect. Dis. 45(5):594-598. Crossref |
||||
|
Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L (2006). Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50(9):2946-2950. Crossref |
||||
|
Lim TP, Tan TY, Lee W, Sasikala S, Tan TT, Hsu LY, Kwa AL (2011). In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore. PLoS One 6(4):e18485. Crossref |
||||
|
Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, Quinn JP, Doern GV (2007). Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J. Clin. Microbiol. 45(10):3352-3359. Crossref |
||||
| Mammina C, Bonura C, Di Bernardo F, Aleo A, Fasciana T, Sodano C, Saporito MA, Verde MS, Tetamo R, Palma DM (2012). Ongoing spread of colistin-resistant Klebsiella pneumoniae in different wards of an acute general hospital, Italy, June to December 2011. Euro Surveill. 17(33) 1-6. | ||||
|
Manchanda V, Sanchaita S, Singh NP (2010). Multidrug resistant Acinetobacter. J. Glob. Infect. Dis. 2(3): 291-304. Crossref |
||||
|
Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J (2000). Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin. Infect. Dis. 31(1):101-106. Crossref |
||||
|
Montefour K, Frieden J, Hurst S, Helmich C, Headley D, Martin M, Boyle DA (2008). Acinetobacter baumannii: an emerging multidrug-resistant pathogen in critical care. Crit. Care Nurse 28(1):15-25. Pubmed |
||||
|
Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, Tubau F, Borraz C, Gudiol F (2004). Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J. Antimicrob. Chemother. 54(6):1085-1091. Crossref |
||||
|
Navon-Venezia S, Leavitt A, Carmeli Y (2007). High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 59(4):772-774. Crossref |
||||
|
Orhan G, Bayram A, Zer Y, Balci I (2005). Synergy tests by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J. Clin. Microbiol. 43(1):140-143. Crossref |
||||
|
Pachon-Ibanez ME, Docobo-Perez F, Lopez-Rojas R, Dominguez-Herrera J, Jimenez-Mejias ME, Garcia-Curiel A, Pichardo C, Jimenez L, Pachon J (2010). Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 54(3):1165-1172. Crossref |
||||
|
Pankey GA Ashcraft DS (2009). The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest and time-kill assay. Diagn. Microbiol. Infect. Dis. 63(2):228-232. Crossref |
||||
|
Pour NK, Dusane DH, Dhakephalkar PK, Zamin FR, Zinjarde SS, Chopade BA (2011). Biofilm formation by Acinetobacter baumannii strains isolated from urinary tract infection and urinary catheters. FEMS Immunol. Med. Microbiol. 62(3):328-338. Crossref |
||||
|
Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J, Davies TA (2012). Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diagn. Microbiol. Infect. Dis. 73(3):267-270. Crossref |
||||
|
Rodriguez CH, De Ambrosio A, Bajuk M, Spinozzi M, Nastro M, Bombicino K, Radice M, Gutkind G, Vay C, Famiglietti A (2010). In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. J. Infect. Dev. Ctries. 4(3):164-167. Crossref |
||||
|
Rodríguez-Hernández MJ, Pachón J, Pichardo C, Cuberos L, Ibá-ez-Martínez J, García-Curiel A, Caballero FJ, Moreno I, Jiménez-Mejías ME (2000). Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J. Antimicrob. Chemother. 45(4):493-501. Crossref |
||||
|
Ruzin A, Keeney D, Bradford PA (2007). AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J. Antimicrob. Chemother. 59(5): 1001-1004. Crossref |
||||
|
Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG (2006). Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42(5):657-668. Crossref |
||||
|
Tan CH, Li J, Nation RL (2007). Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother 51(9):3413-3415. Crossref |
||||
|
Tan TY, Lim TP, Lee WH, Sasikala S, Hsu LY, Kwa AL (2011). In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and Etest methods. Antimicrob. Agents Chemother. 55(1):436-438. Crossref |
||||
|
Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO (2006). In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int. J. Antimicrob. Agents. 27(3):224-228. Crossref |
||||
|
Towner KJ (2009). Acinetobacter: an old friend, but a new enemy. J. Hosp. Infect. 73(4):355-363. Crossref |
||||
|
Urban C, Mariano N, Rahal JJ (2010). In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob. Agents Chemother. 54(6):2732-2734. Crossref |
||||
|
Wareham DW, Bean DC (2006). In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann. Clin. Microbiol. Antimicrob. 5:10. Crossref |
||||
|
Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ (2004). In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 48(3):753-757. Crossref |
||||
|
Zarrilli R, Giannouli M, Tomasone F, Triassi M, Tsakris A (2009). Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. J. Infect. Dev. Ctries. 3(5):335-341. Crossref |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
